Pathways are not trying to restrict or take control of treating the patient from the physician, it’s actually trying to enhance that for the physician and take the guesswork of how to do that out of it, said Rani Khetarpal, MBA, vice president of Oncology Value-Based Partnerships at New Century Health.
Pathways are not trying to restrict or take control of treating the patient from the physician, it’s actually trying to enhance that for the physician and take the guesswork of how to do that out of it, said Rani Khetarpal, MBA, vice president of Oncology Value-Based Partnerships at New Century Health.
Transcript
What is the biggest misconception that clinicians and practices have about pathways?
That they’re super restrictive and trying to control what they do. I think that the biggest pushback we get is that it’s going to take away the ability for the physician to give the patient the treatment they want. I think that is a misconception that as we have 1-to-1 conversations, are able to make sure and clear up; but I think that, and rightfully so, there's always been this perspective because pathways from a New Century Health standpoint have been pushed down because of a payer contract—but now that we’re moving into the provider segment and aligning ourselves with providers, the discussion is a little bit different.
So, the discussion is you can still do for the patients that you need to, you can still prescribe the therapy that you need to, but for a good amount of your patients, you should be able to stay on pathway because it’s what you’re doing anyway. So, once they’re able to look at the pathways and they actually see what is considered, our level 1 pathways, or you know, any pathways that are kind of the primary pathway for that particular tumor type or that patient, then they’re like ‘Okay, this is actually not that bad. We can actually work with this.’ So, the devil is in the details and the devil is in actually looking at the pathways and really understanding what the pathways are trying to do. It’s not trying to restrict and take control of treating the patient from the physician, it’s actually trying to enhance that for the physician and take the guesswork of how to do that out of it.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More